Suchergebnisse - "Zhou, Jianying"

PubPharm (440)

11

Breaking the Mutual Constraint between Polarization and Voltage Resistance with Nanograined High-Entropy Ceramic

enthalten in: ACS applied materials & interfaces | 2024

von Zhou, J. | Zheng, P. | Bai, W. | +3

12

Cigarette smoking inhibits myoblast regeneration by promoting proteasomal degradation of NPAT protein and hindering cell cycle progression

enthalten in: Current research in toxicology | 2024

von Wang, J. | Liu, J. | Shao, J. | +6

13

Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

enthalten in: The New England journal of medicine | 2024

von Drilon, A. | Camidge, D. | Lin, J. | +131

14

Author Correction : Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

enthalten in: Nature cancer | 2024

von Zhou, C. | Wang, Z. | Sun, M. | +31

ErratumFor: Nat Cancer. 2023 Jun;4(6):860-871. - PMID 37322367

15

The pathology biopsy represents the "gold standard" for diagnosis : a case report

enthalten in: Diagnostic microbiology and infectious disease | 2024

von Zhu, L. | Zhang, H. | Gu, H. | +1

16

Construction and validation of a nomogram model to predict the poor prognosis in patients with pulmonary cryptococcosis

enthalten in: PeerJ | 2024

von Tan, X. | Zhang, Y. | Zhou, J. | +2

17

The application of nanopore targeted sequencing for pathogen diagnosis in bronchoalveolar lavage fluid of patients with pneumonia : a prospective multicenter study

enthalten in: Infectious diseases (London, England) | 2024

von Lin, Q. | Yao, Y. | Li, X. | +19

18

HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non-Small Cell Lung Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Jiang, T. | Jin, Q. | Wang, J. | +38

CommentIn: Clin Cancer Res. 2023 Dec 1;29(23):4706-4708. - PMID 37756560

19

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC

enthalten in: The New England journal of medicine | 2023

von Zhou, C. | Solomon, B. | Loong, H. | +122

CommentIn: Cancer Discov. 2023 Dec 12;13(12):OF8. - PMID 37874126

20

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer : a multicentre, open-label, randomised phase 3 study

enthalten in: The Lancet. Respiratory medicine | 2023

von Lu, S. | Zhou, J. | Jian, H. | +41

CommentIn: Lancet Respir Med. 2023 Oct;11(10):857-859. - PMID 37244264